Background {#Sec1}
==========

The number of patients with pulmonary nontuberculous mycobacterium (NTM) is increasing worldwide \[[@CR1], [@CR2]\], with NTM infection in patients in an immunosuppressed state caused by increased use of immunosuppressive or biological agents a serious clinical problem. Isolation of NTM organisms following lung transplantation is reported to occur in 1.5--22.4% \[[@CR3]--[@CR11]\] of those patients, some of whom suffer from pulmonary disease. The most common strain varies among regions and countries, which is an important factor because effective treatment methods differ depending on the causative pathogen. Furthermore, onset period and infection site in the native or transplanted lung are critical for effective treatment.

We report here four cases of NTM pulmonary infection in patients who underwent lung transplantation and were treated at our institution and also review previous reports with focus on onset time and NTM strain. Of 63 patients at our hospital who underwent lung transplantation between January 2000 and January 2018, including heart-lung and living-donor transplantation, four (6.3%) had NTM isolated from obtained specimens, while NTM was not detected in any prior to transplantation. Surveillance bronchoscopy examinations were performed four times the first year and then annually until 5 years after transplantation, according to our institutional protocol. After the fifth year, clinically indicated bronchoscopic examination is occasionally performed when rejection or respiratory infection suspects. In the present cases, clinical samples were obtained from sputum and bronchial lavage samples obtained with bronchoscopy. Mycobacterial cultures were performed using Ogawa medium or a Mycobacteria Growth Indicator Tube system. No *Mycobacterium (M.) tuberculosis* organisms were isolated in any of the present cases.

Case presentations {#Sec2}
==================

Case 1 {#Sec3}
------

An 11-year-old boy with pulmonary arterial hypertension underwent living-donor lung transplantation, with tacrolimus, mycophenolate mofetil (MMF), and prednisolone (PSL) given as immunosuppressive agents. At 76 months after transplantation, *M. gordonae* was isolated from a broncho-alveolar lavage (BAL) sample obtained during a surveillance examination. Contamination was suspected, because even though there were no symptoms, chest computed tomography (CT) showed a slight amount of consolidation in the left upper lesion (Fig. [1](#Fig1){ref-type="fig"}a). PSL as therapeutic and diagnostic treatment was decreased. Sputum culture findings were negative after 5 months, and chest CT images were clear. There was no further NTM detection during the following 15 years.Fig. 1**a**--**d**. Chest computed tomography showing consolidation. **a** Case 1, slight consolidation in left upper lesion caused by *M. gordonae*. **b** Case 2, consolidation in left lower lesion caused by *M. abscessus*. **c** Case 3, consolidation in transplanted lung caused by *M. abscessus*. **d** Case 4, consolidation in native lung caused by *M. intracellulare*

Case 2 {#Sec4}
------

A 38-year-old female with bronchial ectasia underwent living-donor lung transplantation, with ciclosporin, MMF, and PSL given as immunosuppressive agents. At 82 months after transplantation, the patient developed a fever with purulent sputum and chest CT showed consolidation in the left lower lesion (Fig. [1](#Fig1){ref-type="fig"}b). *M. abscessus* complex (MABSC) was isolated from a BAL sample. Following administrations of tazobactam/piperacillin and azithromycin (AZM), as well as a decrease in ciclosporin from 120 to 50 mg for 1 month, the sputum cultures became negative. AZM administration and decreased ciclosporin were continued for 22 months, with no recurrence noted.

Case 3 {#Sec5}
------

A 39-year-old female with lymphangioleiomyomatosis underwent single deceased donor lung transplantation, with ciclosporin, MMF, and PSL given as immunosuppressive agents. At 58 months after transplantation, a fever developed and chest CT showed consolidation in the transplanted lung (Fig. [1](#Fig1){ref-type="fig"}c). MABSC was isolated in a cultured sputum sample. Following administrations of imipenem, amikacin, and AZM for 4 months, sputum culture findings became negative. Maintenance therapy with imipenem and amikacin was given once a week, along with daily AZM and a decrease in MMF, with no recurrence seen during the following 1-year period.

Case 4 {#Sec6}
------

A 41-year-old male with interstitial pneumonia underwent single deceased donor lung transplantation, with ciclosporin, MMF, and PSL given as immunosuppressive agents. At 12 months after transplantation, a fever developed and chest CT showed consolidation in the native lung (Fig. [1](#Fig1){ref-type="fig"}d), which was suspected to be pneumonia caused by general bacteria. Broad-spectrum antibiotic therapy was started, though was not effective. After a period of time, *M. intracellulare* was isolated from a cultured sputum sample. Thereafter, rifampicin (RFP), ethambutol, and clarithromycin (REC) treatment was administered for 3 months, after which sputum findings were negative. Rifampicin was continued at 800 mg, the standard level, while ciclosporin was adjusted according to trough level and finally administered at 550--600 mg, three times the normal dose, and PSL was gradually reduced. The patient died after 21 months because of respiratory failure due to chronic rejection, though sputum culture findings remained negative with REC treatment These cases are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Summary of 4 casesCase No.AgeSexPrimary diseaseDonarProcedurePeriod to onset^a^ (Month)OrganismInfection lungSymptomDiagnosisDrugPeriod to negative conversion (month)Treatment period (month)Reinfectionoutcome110MPAHLivingBilateralLate (76)M.gordonaeTransplantedNoneBALNone5--NoneAlive235FBELivingBilateralLate (82)MABSCTransplantedFever\
SputumBALTAZ/PIPC+AZM122NoneAlive341FLAMCadavericSingleLate (58)MABSCTransplantedSputumSptumAZM + IPM + AMK412NoneAlive439MNSIPCadavericSingleEarly (12)M.intracellurareNativeFeverSptumREC321NoneDead*AZM* azithromycin, *BAL* broncho-alveolar lavage, *BE* bronchiectasis, *CyA* Cycrosporin, *LAM* lymphangioleiomyomatosis, *M.* Mycobacterium, *MMF* mycophenolate mofetil, *NSIP* nonspecific interstitial puemonia, *PAH* pulmonary arterial hypertension, *PSL* prednisolone, *REC* Rifampicin, ethambutol, and clarithromycin^a^Early onset considered to occur within 180 days, late onset from 180 days until 3 years, and very late onset after 3 years

Discussion {#Sec7}
==========

The number of patients worldwide with pulmonary NTM disease is increasing \[[@CR1], [@CR2]\]. An NTM infection is not contagious, whereas an MABSC infection can be acquired through transmission, potentially via fomites or aerosols \[[@CR12]\]. Floto et al. reported that an NTM infection occurring in patients with cystic fibrosis can be problematic, as that can influence the indication for lung transplantation \[[@CR13]\].

NTM infection following transplantation is a critical issue, because treatment is difficult, especially for patients in an immunosuppressed condition, as there is no specific medicine available for NTM, unlike *M. tuberculosis*. In hematopoietic stem cell or other solid organ recipients, the most common site of infection is the lung, with *M. avium* complex (MAC), the most commonly noted causative pathogen, followed by *M. kansasii* \[[@CR14], [@CR15]\]. Other studies have suggested that NTM infection rates of incidence in lung transplant recipients range from 1.5--22.4% (Table [2](#Tab2){ref-type="table"}) \[[@CR3]--[@CR11]\]. In those reports, MAC was most common, followed by MABSC, while *M. kansasii* was not a major concern. However, there are also reports of rare types of NTM (Table [3](#Tab3){ref-type="table"}), though the causative pathogens vary depending on region. In those cases, the most common infection site is a lung, followed by skin and soft tissue caused by rapid growers, such as MABSC or *M. gordonae*.Table 2Previous reports of NTM lung infection after lung transplantTable 3Pathogens classified by onset timeEarlyLateVery late(*n* = 43)(*n* = 35)(*n* = 16)MAC^a^4135MABSC^b^11109M.gordonae101M.chelonae100M.siminae010M.kansasii010M.fortuitum030M.asiaticum001Not reported2670^a^*MAC* mycobacterium avium complex^b^*MABSC* Mycobacterium abscessus complex

We reviewed previous reports and classified those cases based on onset time after transplantation, with early onset considered to occur within 180 days, late onset from 180 days until 3 years, and very late onset after 3 years. There were 212 cases in which onset time was described (early onset, *n* = 43; late onset, *n* = 35; very late onset, *n* = 16) (Table [2](#Tab2){ref-type="table"}), including 61 with both types of pathogens and onset time details (Table [3](#Tab3){ref-type="table"}). MAC and MABSC were common organisms regardless of time of onset. In cases of early onset, the origin of NTM was newly acquired in some and prior to transplantation or donor-derived in others. On the other hand, patients in the very late onset group acquired a new infection under an immunosuppressed condition. All 16 cases had respiratory symptoms due to NTM pulmonary disease (Table [4](#Tab4){ref-type="table"}). The average time from transplantation to onset was 6.1 years, and prognosis in most was good (Table [4](#Tab4){ref-type="table"}). The direct cause of the three mortalities was not NTM, but rather bronchiolitis obliterans syndrome (BOS) in one \[[@CR3]\], and either aspergillus or pneumonia infection in two \[[@CR6]\].Table 4Details of very late onset reported cases0ReferencesAgeSexReason fot LuTxLuTxTime to onsetSymptomsChest X-ray findingsCulturePathogenDrug for treatmentOutcome11999Malouf \[[@CR3]\]55FPAHHL8.9 yearsCough, sputum, dyspnea, feverNormalSputumMABSCRi + C + CiAlive238MCHDHL4.3 yearsCough, sputum, dyspnea, feverBilateral apical infiltrateBALM.aviumR + E + C + CiAlive345FEmpysemaSL3.6 yearsCough, sputum, dyspnea, feverBasal infiltratesBALMACRi + C + CiAlive432MAATDSL3.6 yearsCough, dyspnea, feverApical and mid-zone infiltratesSputumMACRi + C + CiDead554MEmpysemaSL3.7 yearsCough, sputum, dyspnea, feverConsolidation in midzoneBALM.aviumNo treatmentAlive648MAATDSL3.3 yearsCough, sputum, dyspnea, feverInfiltrate in transpranted lungPleural fliudM.asiaticumR + E + PAlive72002Fairhurst \[[@CR5]\]55FPAHHL9.0 yearsCough, sputum, dyspnea, fever--BALMABSCRi + C + CiAlive82006Chernenko \[[@CR6]\]40FEisenmengerHL9.1 yearsFever, chills--SputumMABSCR + C + CiDead948MCOPDSL8.4 yearsFever, chills--BAL + sputumMABSCR + E + CDead1053MCOPDBL8.5 yearsSputumNormalBAL + sputumMABSCR + E + CiAlive1139MCFBL9.3 yearsSputumNodulesSputumMABSCRi + C + Ci + EAlive1242FLAMBL4.1 yearsSputumNodulesSputumMABSCAMK + AZ + cefoxitin+CiAlive132012Knoll \[[@CR8]\]28FCFBL3.2 years----BALM.avium--Alive142018Our study10MPAHLDLT6.3 yearsNoneApical infiltratesBALM.godnaeno treatmentAlive1535FBELDLT6.8 yearsFever, sputumBasal infiltratesBALMABSCTAZ/PIPC+AZMAlive1641FLAMSL4.8 yearsSputumBasal infiltratesSputumMABSCAZM + IPM + AMKAlive*AATD* α 1-antitrypsin deficiency, *AMK* amikacin, *AZM* azithromycin, *BAL* bronchoalveolar lavage, *BE* bronchiectasis, *BL* bilatetal lung, *C* Clarithromycin, CF cystic fibrosis, *CHD* congenital heart disease, *Ci* ciprofloxacin, *COPD* chronic obstructive pulmonary disease, *E* Ethambutol, *HL* heart-lung, *IPM* imipenem, *LAM* lymphangioleiomyomatosis, *LDLT* living donor lung transplantation, *P* Pyridoxal Phosphate Hydrate, *PAH* pulmonary arterial hypertension, *R* rifampicin, *Ri* Rifabutin, *SL* single lung, *TAZ/PIPC* Tazobactam / Piperacillin

Chronic rejection is known to be associated with NTM infection \[[@CR3]\], and bronchiolitis obliterans syndrome is likely to occur in patients with NTM detected \[[@CR7], [@CR9]\]. Most of the patients in our cohort had respiratory symptoms, such as cough, sputum, and fever, with imaging showing consolidation suggesting pneumonia, and were diagnosed based on sputum culture or BAL results. Aggravation of a pulmonary infection in cases affected by immunosuppression will occur if an inappropriate antibiotic medicine is administered. Sputum obtained by expectoration may not be representative of sputum from deeper parts; thus, it is useful to first perform BAL to detect pathogens with the possibility of a combined infection of acid-fast bacteria or fungus kept in mind. The percentage of patients with MABSC was high (56.3%), which included therapy resistant cases ending in death from respiratory failure, though that rate may be falsely high because of selection bias. It is important for physicians to be aware that the risk of NTM infection continues for a long period after transplantation, as that was previously reported to occur in a patient after 9 years \[[@CR6]\], and such occurrence may be via the same mechanism seen in the general population. NTM can destroy the lung structure, leading to decreased respiratory function \[[@CR12]\]. Thus, care must be taken regarding reduction of immunosuppressive agents because respiratory function can worsen if rejection occurs. In most reports, overall survival after lung transplantation was not influenced by NTM infection \[[@CR8], [@CR9]\], though George et al. found that the survival rate of pulmonary NTM disease was lower than that of subclinical infection cases \[[@CR10]\]. On the other hand, another investigation found that it was similar between cases of single lung transplantation and those with BOS \[[@CR7]\].

Selection of the optimum antibiotic medication for treatment is crucial, though dependent on the sensitivity of each pathogen according to the ATS guidelines and must also be adjusted in accordance with the prescribed immunosuppressive agents. On the other hand, that is dependent on individual patient state regarding which agents can be reduced. PSL was decreased in two of our cases and only case 1 showed improvement with treatment. RFP, administered for MAC, attenuates the effect of ciclosporin; thus, it is necessary to increase its dose by 3--5 times above the standard when administered. The present case 4 was given an approximately threefold greater dose of ciclosporin while receiving the standard RFP dosage. Ciclosporin must be adjusted by monitoring its concentration in blood, as that varies in each patient from a variety of factors.

Conclusions {#Sec8}
===========

An NTM infection and pulmonary disease can occur several years following lung transplantation. It is necessary to consider the best treatment for affected patients based on the pathogens involved, individual status, and disease severity, including which antibiotic medicine should be selected and which immunosuppressive agent can be decreased.
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P
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:   Pulmonary arterial hypertension
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:   Prednisolone

R

:   Rifampicin
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:   Rifampicin, ethambutol, and clarithromycin

RFP

:   Rifampicin

Ri

:   Rifabutin
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:   Single lung
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